CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)
$3.76 -0.195 (-4.9305%)
Analysed CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) News Sources
CytomX Therapeutics to Present at Upcoming June Investor Conferences
21-05-2026
yahoo.com
How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data And Risks
28-05-2026
yahoo.com
CytomX (CTMX) Q4 2025 Earnings Transcript
02-06-2026
fool.com
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
03-06-2026
yahoo.com
Why Regeneron (REGN) Stock Is Trading Up Today
04-06-2026
yahoo.com
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
04-06-2026
yahoo.com
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
05-06-2026
yahoo.com
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments
11-06-2026
yahoo.com
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
19-06-2026
yahoo.com
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
08-07-2026
yahoo.com
What is the current price of CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)?
The current price of CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) is $3.76.
CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) absolute price change since previous trading day?
The absolute price change of CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) since the previous trading day is $-0.195.
CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) percentage price change since previous trading day?
The percentage price change of CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) since the previous trading day is -4.9305%.
What is the most recent average sentiment score for CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)?
The most recent average sentiment score for CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)?
The most recent sentiment for CYTOMX THERAPEUTICS INC (CTMX:NASDAQ) is .
SEC-8K** Filing Available For CYTOMX THERAPEUTICS INC (CTMX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.